Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiotherapy Combined with Iparomlimab and Tuvonralimab for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Apr 2025: Trial registered, NCT06936748
  2. 20 Jun 2025: Trial started, NCT06936748

The trials

NCT06936748: SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors

State
Under way
Phase
Phase 2
People
30 planned
Started
20 Jun 2025
Primary completion
19 Jun 2028
Arms
Radiotherapy Combined with Immunotherapy
Results
None posted
  1. 20 Apr 2025: Trial registered
  2. 20 Jun 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.